SCHEMBL34052

SCHEMBL34052

OCCCCCCSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 20/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28634657 1.00 KIF11 (0.55) KIF11
SCHEMBL8447104 1.00 KIF11 (0.55) KIF11
SCHEMBL3727708 0.92 KIF11 (0.59) KIF11
SCHEMBL974722 0.84 KIF11 (0.63) KIF11
SCHEMBL9889271 0.82 KIF11 (0.45) KIF11
SCHEMBL4534194 0.82 KIF11 (0.45) KIF11
SCHEMBL6909006 0.81 KIF11 (0.55) KIF11
SCHEMBL5350718 0.81 KIF11 (0.55) KIF11
SCHEMBL21093254 0.81 KIF11 (0.55) KIF11
SCHEMBL5357811 0.81 KIF11 (0.55) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345457-A1 FUNCTIONALIZED DIBLOCK COPOLYMER AND ITS PREPARATION METHOD AND APPLICATION InnovatingBio (Shanghai) Co.,Ltd. (CN) 2025-11-13 US disclosed
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE ASCENDIS PHARMA A/S (DK) 2025-04-24 US disclosed
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA GMBH (DE) 2024-02-08 US disclosed
EP-4239009-A9 FUNCTIONALIZED DIBLOCK COPOLYMER, AND PREPARATION METHOD THEREFOR AND USE THEREOF Innovatingbio (Shanghai) Co., Ltd. (CN) 2024-01-10 EP disclosed
EP-4239009-A9 FUNCTIONALIZED DIBLOCK COPOLYMER, AND PREPARATION METHOD THEREFOR AND USE THEREOF Innovatingbio (Shanghai) Co., Ltd. (CN) 2024-01-10 EP disclosed
EP-4239009-A1 FUNCTIONALIZED DIBLOCK COPOLYMER, AND PREPARATION METHOD THEREFOR AND USE THEREOF Innovatingbio (Shanghai) Co., Ltd. (CN) 2023-09-06 EP disclosed
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate ASCENDIS PHARMA A/S (DK) 2022-10-20 US disclosed
EP-3981761-A2 INTERMEDIATES FOR PRODRUGS Ascendis Pharma A/S (DK) 2022-04-13 EP disclosed
EP-2596805-B1 Prodrug comprising a drug-linker conjugate ASCENDIS PHARMA AS (DK) 2021-10-27 EP disclosed
US-10961263-B2 Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-03-30 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
EP-2596805-A1 Prodrug comprising a drug linker conjugate Ascendis Pharma A/S (DK) 2013-05-29 EP disclosed
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS ASCENDIS PHARMA A/S (DK) 2013-02-07 US disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed
EP-2237799-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER Ascendis Pharma AS (DK) 2010-10-13 EP disclosed
WO-2009095479-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2009-08-06 WO disclosed
EP-0202758-B1 HYBRIDIZATION METHOD AND PROBES THEREFOR Zeneca Limited (GB) 1991-09-25 EP disclosed
EP-0202758-A1 Hybridization method and probes therefor ZENECA LIMITED (GB) 1986-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035635-A1 CARRIER-LINKED CARBAMATE PRODRUG LINKERS CTSL, SLC16A7, SLC16A8 KIF11 1805/4885
US-10961263-B2 Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery SLC29A1, SLC29A2, SLC7A1 KIF11 909/4885
US-20250345457-A1 FUNCTIONALIZED DIBLOCK COPOLYMER AND ITS PREPARATION METHOD AND APPLICATION VEGFA, FOLR2, FGB KIF11 267/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KIF11 3244/4885
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 KIF11 3253/4885
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate H1-0, H1-3, DLST KIF11 3239/4885
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE H1-0, H1-3, DLST KIF11 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.